ADC Therapeutics SA
1.44USD
-0.1600 (-10.00%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ADCT.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.21▲ | -$0.22 | 1 | 0 |
| Next quarter | -$0.2▲ | -$0.2 | 1 | 1 |
| Current year | -$0.75▲ | -$0.86 | 4 | 0 |
| Next year | -$0.68▼ | -$0.66 | 0 | 2 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.22 | -$0.11 | +0.11 (+49.1%) |
| 2026-03-31 | -$0.2 | -$0.21 | -0.01 (-4.1%) |
| 2025-12-31 | -$0.27 | -$0.04 | +0.23 (+85.1%) |
| 2025-09-30 | -$0.36 | -$0.3 | +0.06 (+17.4%) |
76 ratings from 12 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Guggenheim | Maintained | Buy | $10 $5 | Aug 17, 2026 |
| HC Wainwright & Co. | Downgraded from Buy | Neutral | — | Jun 8, 2026 |
| RBC Capital | Downgraded from Outperform | Sector Perform | $6 $2 | Jun 4, 2026 |
| RBC Capital | Reiterated | Outperform | $6 | May 5, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $8 | May 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $7 $8 | Mar 23, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $8 $7 | Oct 16, 2025 |
| Guggenheim | Reiterated | Buy | $10 | Aug 13, 2025 |
| RBC Capital | Maintained | Outperform | $8 $5 | Jun 20, 2025 |
| Guggenheim | Maintained | Buy | $7 $10 | Jun 13, 2025 |
| RBC Capital | Reiterated | Outperform | $8 | May 15, 2025 |
| Guggenheim | Maintained | Buy | $10 $7 | Mar 31, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $8 | Mar 31, 2025 |
| Cantor Fitzgerald | Reiterated | Overweight | — | Mar 7, 2025 |
| Stephens & Co. | Maintained | Overweight | $6 $8 | Feb 24, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $8 | Jan 6, 2025 |
| Guggenheim | Reiterated | Buy | $10 | Dec 12, 2024 |
| HC Wainwright & Co. | Reiterated | Buy | — | Dec 11, 2024 |
| Stephens & Co. | Initiated | Overweight | $6 | Nov 8, 2024 |
| HC Wainwright & Co. | Reiterated | Buy | $8 | Aug 8, 2024 |
| RBC Capital | Reiterated | Outperform | $8 | Aug 7, 2024 |
| Cantor Fitzgerald | Initiated | Overweight | — | May 30, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $9 $8 | May 7, 2024 |
| HC Wainwright & Co. | Reiterated | Buy | $9 | Apr 15, 2024 |
| Guggenheim | Reiterated | Buy | — | Apr 5, 2024 |
31 filings from 13 insiders · 0 buy / 0 sell over 6m
Officers and directors of ADCT, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| GRAHAM PETER JOfficer | Grant | 221.1k | — | — | Jun 30, 2026 |
| CARMONA JOSEChief Financial Officer | Grant | 203.7k | — | — | Jun 30, 2026 |
| MALLIK AMEETChief Executive Officer | Grant | 675.0k | — | — | Jun 30, 2026 |
| ZAKI MOHAMEDOfficer | Grant | 213.9k | — | — | Jun 30, 2026 |
| COUGHLIN TIMOTHY PDirector | Grant | 45.0k | — | — | Jun 1, 2026 |
| SQUARER RON RDirector | Grant | 45.0k | — | — | Jun 1, 2026 |
| BIZZARI JEAN-PIERREDirector | Grant | 45.0k | — | — | Jun 1, 2026 |
| SANDOR VICTORDirector | Grant | 45.0k | — | — | Jun 1, 2026 |
| AZELBY ROBERT WDirector | Grant | 45.0k | — | — | Jun 1, 2026 |
| MONGES VIVIANEDirector | Grant | 45.0k | — | — | Jun 1, 2026 |
| HUG PETERDirector | Grant | 45.0k | — | — | Jun 1, 2026 |
| REDMILE GROUP, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sellindirect | 5.88M | $3.28 | $19.64M | Apr 2, 2026 |
| GRAHAM PETER JOfficer | Grant | 294.8k | $3.99 | $1.18M | Feb 13, 2026 |
| CARMONA JOSEChief Financial Officer | Grant | 271.6k | $3.99 | $1.08M | Feb 13, 2026 |
| MALLIK AMEETChief Executive Officer | Grant | 900.0k | $3.99 | $3.59M | Feb 13, 2026 |
| ZAKI MOHAMEDOfficer | Grant | 285.2k | $3.99 | $1.14M | Feb 13, 2026 |
| KALLEBO LISA MICHELLEOfficer | Grant | 62.9k | $3.99 | $251k | Feb 13, 2026 |
| COUGHLIN TIMOTHY PDirector | Grant | 40.0k | — | — | Jun 3, 2025 |
| SQUARER RON RDirector | Grant | 40.0k | — | — | Jun 3, 2025 |
| BIZZARI JEAN-PIERREDirector | Grant | 40.0k | — | — | Jun 3, 2025 |
Analyst Ratings
3 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 3 | 2 | 0 | 0 | Buy2.40 |
| 1 mo ago | 0 | 3 | 2 | 0 | 0 | Buy2.40 |
| 2 mo ago | 0 | 3 | 2 | 0 | 0 | Buy2.40 |
Members whose judged calls on ADCT have played out most reliably.
No settled calls on ADCT yet. 1 call is open, the first due Sep 4, 2027.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice